ImmunoPrecise Antibodies Ltd. (HYFT) - Total Assets
Based on the latest financial reports, ImmunoPrecise Antibodies Ltd. (HYFT) holds total assets worth $26.10 Million USD as of October 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ImmunoPrecise Antibodies Ltd. - Total Assets Trend (1997–2025)
This chart illustrates how ImmunoPrecise Antibodies Ltd.'s total assets have evolved over time, based on quarterly financial data. Also see market cap of ImmunoPrecise Antibodies Ltd. for the company's overall valuation and market capitalisation.
ImmunoPrecise Antibodies Ltd. - Asset Composition Analysis
Current Asset Composition (April 2025)
ImmunoPrecise Antibodies Ltd.'s total assets of $26.10 Million consist of 42.2% current assets and 57.8% non-current assets. Review ImmunoPrecise Antibodies Ltd. (HYFT) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 24.0% |
| Accounts Receivable | $4.81 Million | 10.8% |
| Inventory | $2.10 Million | 4.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.07 Million | 2.4% |
| Goodwill | $8.23 Million | 18.5% |
Asset Composition Trend (1997–2025)
This chart illustrates how ImmunoPrecise Antibodies Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ImmunoPrecise Antibodies Ltd. (HYFT) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ImmunoPrecise Antibodies Ltd.'s current assets represent 42.2% of total assets in 2025, a decrease from 67.1% in 1997.
- Cash Position: Cash and equivalents constituted 24.0% of total assets in 2025, up from 9.2% in 1997.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 20.0% of total assets, an increase from 0.0% in 1997.
- Asset Diversification: The largest asset category is goodwill at 18.5% of total assets.
ImmunoPrecise Antibodies Ltd. Competitors by Total Assets
Key competitors of ImmunoPrecise Antibodies Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
ImmunoPrecise Antibodies Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.19 | 1.01 | 3.06 |
| Quick Ratio | 4.09 | 0.85 | 2.92 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $16.55 Million | $93.00K | $16.15 Million |
ImmunoPrecise Antibodies Ltd. - Advanced Valuation Insights
This section examines the relationship between ImmunoPrecise Antibodies Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.59 |
| Latest Market Cap to Assets Ratio | 1.38 |
| Asset Growth Rate (YoY) | -25.9% |
| Total Assets | $44.44 Million |
| Market Capitalization | $61.17 Million USD |
Valuation Analysis
Above Book Valuation: The market values ImmunoPrecise Antibodies Ltd.'s assets above their book value (1.38x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: ImmunoPrecise Antibodies Ltd.'s assets decreased by 25.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ImmunoPrecise Antibodies Ltd. (1997–2025)
The table below shows the annual total assets of ImmunoPrecise Antibodies Ltd. from 1997 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-04-30 | $44.44 Million | -25.92% |
| 2024-04-30 | $59.99 Million | -22.91% |
| 2023-04-30 | $77.81 Million | -16.77% |
| 2022-04-30 | $93.49 Million | +39.63% |
| 2021-04-30 | $66.96 Million | +145.60% |
| 2020-04-30 | $27.26 Million | -3.82% |
| 2019-04-30 | $28.35 Million | +15.34% |
| 2018-04-30 | $24.58 Million | +525.49% |
| 2017-04-30 | $3.93 Million | +184.62% |
| 2016-04-30 | $1.38 Million | +2893.23% |
| 2015-04-30 | $46.12K | -67.59% |
| 2014-04-30 | $142.29K | +184.73% |
| 2013-04-30 | $49.97K | -46.39% |
| 2012-04-30 | $93.22K | -55.82% |
| 2011-04-30 | $211.00K | -96.14% |
| 2010-04-30 | $5.47 Million | -21.18% |
| 2009-04-30 | $6.93 Million | +34.39% |
| 2008-04-30 | $5.16 Million | -7.16% |
| 2007-04-30 | $5.56 Million | +37.35% |
| 2006-04-30 | $4.05 Million | -5.34% |
| 2005-04-30 | $4.28 Million | +195.95% |
| 2004-04-30 | $1.44 Million | +55.63% |
| 2003-04-30 | $928.23K | +5.57% |
| 2002-04-30 | $879.28K | -24.13% |
| 2001-04-30 | $1.16 Million | +185.01% |
| 2000-04-30 | $406.64K | -75.44% |
| 1999-04-30 | $1.66 Million | -43.50% |
| 1998-04-30 | $2.93 Million | -24.42% |
| 1997-04-30 | $3.88 Million | -- |
About ImmunoPrecise Antibodies Ltd.
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock ther… Read more